rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2016-12-5-503-508rpcardio-1328Research ArticleORIGINAL STUDIESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯEndothelium Protective Function of Statins in Men and Women with Coronary AtherosclerosisЭндотелийпротективная функция статинов у мужчин и женщин с коронарным атеросклерозомКлимушинаМ. В.KlimushinaM. V.

к.б.н., с.н.с. отдела изучения биохимических маркеров риска хронических неинфекционных заболеваний ГНИЦ ПМ

PhD, Senior Researcher, Department of Study of Biochemical Risk Markers of Chronic Non-Communicable Diseases, State Research Centre for Preventive Medicine

mklimushina@gmail.comГумановаН. Г.GumanovaN. G.

к.б.н., в.н.с. отдел изучения биохимических маркеров риска хронических неинфекционных заболеваний ГНИЦ ПМ

PhD, Leading Researcher, Department of Study of Biochemical Risk Markers of Chronic Non-Communicable Diseases, State Research Centre for Preventive Medicine

ГоршковА. Ю.GorshkovA. Ju.

аспирант отдела клинической кардиологии и молекулярной генетики ГНИЦ ПМ

MD, Graduate Student, Department of Clinical Cardiology and Molecular Genetics, State Research Centre for Preventive Medicine

ГавриловаН. Е.GavrilovaN. E.

к.м.н., с.н.с. отдела клинической кардиологии и молекулярной генетики ГНИЦ ПМ

MD, PhD, Senior Researcher, Department of Clinical Cardiology and Molecular Genetics, State Research Centre for Preventive Medicine

МетельскаяВ. А.Metel'skajaV. A.

д.б.н. профессор, руководитель отдела изучения биохимических маркеров риска хронических неинфекционных заболеваний ГНИЦ ПМ

PhD, Professor, Head of Department of Study of Biochemical Risk Markers of Chronic Non-Communicable Diseases, State Research Centre for Preventive Medicine

БойцовС. А.BoytsovS. A.

д.м.н., профессор, директор ГНИЦ ПМ

MD, PhD, Professor, Head of State Research Centre for Preventive Medicine

Государственный научно-исследовательский центр профилактической медицины Россия, 101990, Москва, Петроверигский пер., 10, стр 3РоссияState Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 RussiaRussian Federation201606112016125503508Copyright © Klimushina M.V., Gumanova N.G., Gorshkov A.J., Gavrilova N.E., Metel'skaja V.A., Boytsov S.A., 20162016Климушина М.В., Гуманова Н.Г., Горшков А.Ю., Гаврилова Н.Е., Метельская В.А., Бойцов С.А.Klimushina M.V., Gumanova N.G., Gorshkov A.J., Gavrilova N.E., Metel'skaja V.A., Boytsov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1328Aim

Aim. To study the relationship between serum endothelin levels and lipid-lowering therapy in patients with confirmed coronary atherosclerosis.

Material and methods

Material and methods. Patients (n=447; 320 men and 127 women; mean age 62.7±8.8 years) with coronary atherosclerosis, confirmed by coronary angiography, were included into the study. Serum endothelin levels were assessed by enzyme immunoassay (ELISA).

Results

Results. Negative correlation between the statins receiving and serum endothelin level was found in men (r=-0.11; p=0.04). Serum endothelin level was 1.8 times lower in men who received statins, compared with men without statin therapy. The relationship between statins receiving and serum endothelin level was not found in women with coronary atherosclerosis.

Conclusion

Conclusion. The statins receiving in men with coronary atherosclerosis, in contrast to women, negatively correlated with serum endothelin level and is associated with its almost twofold reduction. Relationship between serum endothelin level and receiving other drugs was not found.

Цель

Цель. Изучить взаимосвязь между уровнем эндотелина и приемом гиполипидемических препаратов у пациентов с верифицированным поражением коронарных артерий.

Материал и методы

Материал и методы. В исследование было включено 447 пациентов (320 мужчин и 127 женщин) в возрасте 62,7±8,8 лет с атеросклеротическим поражением коронарных артерий, подтвержденным методом коронароангиографии. Уровень эндотелина в сыворотке крови измеряли методом иммуноферментного анализа (ELISA).

Результаты

Результаты. Выявлена отрицательная корреляция между приемом статинов и уровнем эндотелина у мужчин (r=-0,11; p=0,04). У мужчин, принимающих статины (n=309), уровень эндотелина в 1,8 раз ниже по сравнению с мужчинами, не принимающими статины. У женщин с атеросклеротическим поражением коронарных артерий взаимосвязи между приемом статинов и уровнем эндотелина в сыворотке крови не выявлено.

Заключение

Заключение. У мужчин с атеросклеротическим поражением коронарных артерий, в отличие от женщин, прием статинов отрицательно коррелирует с уровнем эндотелина и ассоциирован почти с двукратным его снижением. Взаимосвязи между концентрацией эндотелина и приемом других лекарственных препаратов не выявлено.

атеросклерозэндотелиальная дисфункцияэндотелинстатиныatherosclerosisendothelial dysfunctionendothelinstatinsReferencesMudau M., Genis A., Lochner A., et al. Endothelial dysfunction – the early predictor of atherosclerosis. Cardiovasc J Afr 2012;23(4):222-31.Mudau M., Genis A., Lochner A., et al. Endothelial dysfunction – the early predictor of atherosclerosis. Cardiovasc J Afr 2012;23(4):222-31.Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95.Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95.Davenport A.P., Hyndman K.A., Dhaun N., et al. Endothelin. Pharmacol Rev 2016;68:357-418.Davenport A.P., Hyndman K.A., Dhaun N., et al. Endothelin. Pharmacol Rev 2016;68:357-418.Doggrell S.A. The endothelin system and its role in acute myocardial infarction. Expert Opin Ther Targets 2004;8(3):191-201.Doggrell S.A. The endothelin system and its role in acute myocardial infarction. Expert Opin Ther Targets 2004;8(3):191-201.Gottlieb S.S., Harris K., Todd J., et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clin Biochem 2015;48(4-5):292-6.Gottlieb S.S., Harris K., Todd J., et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clin Biochem 2015;48(4-5):292-6.Sainani G.S., Maru V.G., Mehra A.P. Role of endothelin-1 in genesis of coronary artery disease. Indian Heart J 2005;57(2):121-7.Sainani G.S., Maru V.G., Mehra A.P. Role of endothelin-1 in genesis of coronary artery disease. Indian Heart J 2005;57(2):121-7.Bossard M., Pumpol K., van der Lely S., et al. Plasma endothelin-1 and cardiovascular risk among young and healthy adults. Atherosclerosis 2015;239(1):186-91.Bossard M., Pumpol K., van der Lely S., et al. Plasma endothelin-1 and cardiovascular risk among young and healthy adults. Atherosclerosis 2015;239(1):186-91.Hirata Y., Nagata D., Suzuki E., et al. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. Int Heart J 2010;51(1):1-6.Hirata Y., Nagata D., Suzuki E., et al. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. Int Heart J 2010;51(1):1-6.RadenkovićM., StojanovićM., Potpara T. et al. Therapeutic Approach in the Improvement of Endothelial Dysfunction: The Current State of the Art. Biomed Res Int 2013;2013:252158.RadenkovićM., StojanovićM., Potpara T. et al. Therapeutic Approach in the Improvement of Endothelial Dysfunction: The Current State of the Art. Biomed Res Int 2013;2013:252158.Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87.Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87.Miller P.E., Martin S.S. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep 2016;18(5):20.Miller P.E., Martin S.S. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep 2016;18(5):20.Souza-Costa D.C., Sandrim V.C., Lopes L.F., et al. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007;193(2):438-44.Souza-Costa D.C., Sandrim V.C., Lopes L.F., et al. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007;193(2):438-44.Hosokawa S., Hiasa Y., Tomokane T., et al. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol 2006;29(8):357-62.Hosokawa S., Hiasa Y., Tomokane T., et al. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol 2006;29(8):357-62.Ridker P.M., Cannon C.P., Morrow D., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20-8.Ridker P.M., Cannon C.P., Morrow D., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20-8.Liao J.K. and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45: 89-118.Liao J.K. and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45: 89-118.Puccetti L., Pasqui A.L., Pastorelli M.,Bova G., et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002;32(12):901-8.Puccetti L., Pasqui A.L., Pastorelli M.,Bova G., et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002;32(12):901-8.Ito T., Ikeda U., Shimpo M., et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002;16(2):121-6.Ito T., Ikeda U., Shimpo M., et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002;16(2):121-6.Eberlein M., Heusinger-Ribeiro J., Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133(7):1172-80.Eberlein M., Heusinger-Ribeiro J., Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133(7):1172-80.Plenge J.K., Hernandez T. L., Weil K.M., et al. Simvastatin Lowers C-Reactive Protein Within 14 Days An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction. Circulation 2002;106:1447- 52.Plenge J.K., Hernandez T. L., Weil K.M., et al. Simvastatin Lowers C-Reactive Protein Within 14 Days An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction. Circulation 2002;106:1447- 52.Muraca M., Baggio G., Miconi L., et al. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation. Eur J Clin Invest 1991;21(2):204-8.Muraca M., Baggio G., Miconi L., et al. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation. Eur J Clin Invest 1991;21(2):204-8.Sahebkar A., Kotani K., Serban C., et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 2015;241(2):433-42.Sahebkar A., Kotani K., Serban C., et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 2015;241(2):433-42.Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25.Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25.Hernández-Perera O., Pérez-Sala D., Navarro-Antolín J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101(12):2711-9.Hernández-Perera O., Pérez-Sala D., Navarro-Antolín J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101(12):2711-9.Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104(4):376-9.Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104(4):376-9.Polderman K.H., Stehouwer C.D., van Kamp GJ, et al. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993;118(6):429-32.Polderman K.H., Stehouwer C.D., van Kamp GJ, et al. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993;118(6):429-32.Schooling C.M., Au Yeung S.L., Freeman G., et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57.Schooling C.M., Au Yeung S.L., Freeman G., et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57.

The authors declare that there are no conflicts of interest present.